Metsera’s Phase IIb GLP-1 Data Show Competitive Efficacy, Tolerability

 
• By Joseph Haas
  
DATA_Puzzle Piece_186976547_1200.jpg
Metsera reported new data on an obesity candidate key to Pfizer's planned $4.9bn buyout

More from Strategy

More from Business